In the last few years, medications like tirzepatide have drawn...
Read MoreSupplying Tirzepatide, Semaglutide, and Retatrutide for controlled scientific research and laboratory analysis across the UK.
Explore commonly referenced peptides used in metabolic research
Well-established GLP-1 receptor agonist used in research studies.
View Semaglutide
Dual GIP/GLP-1 peptide studied in metabolic pathway research.
View Tirzepatide
Triple-agonist compound under advanced metabolic research.
View RetatrutideOur Focus is consistency, transparency, and reliable UK fulfilment.
Each batch is independently tested, with full certificates available for transparency
Maintained batch consistency helps support more reliable research conditions
Part of the HWS Labs Group, with laboratory operations established in Europe since 2012.
Private access to materials with secure checkout and data protection.
Not all research materials are handled the same way, peptide quality and handling can vary between suppliers. At TrimFast you're guaranteed consistent batches and reliable fulfilment to help ensure more dependable results.
View Available CompoundsOngoing research into metabolic peptides focuses on how signalling pathways influence appetite regulation, energy balance, and broader endocrine processes.
GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone involved in appetite signalling and glucose regulation. Research in this area explores how receptor activation may influence metabolic pathways and energy intake behaviour.
More recent compounds are studied for their interaction with multiple signalling pathways, including GIP and glucagon receptors. These combined mechanisms are an active area of investigation in metabolic research environments.
Compounds such as Tirzepatide, Semaglutide, and Retatrutide are frequently referenced in ongoing studies examining appetite signalling, satiety responses, and metabolic function under controlled conditions.
Tirzepatide, Semaglutide and Retatrutide are studied for their interaction with metabolic signalling pathways, each offering a different level of complexity and research focus.
✓ GLP-1 pathway focus
✓ Consistent signalling interaction
✓ Widely studied compound
✓ Dual GIP/GLP-1 interaction
✓ Broader signalling approach
✓ Next-generation compound
✓ Triple pathway interaction
✓ Energy + metabolic signalling
✓ Advanced research compound
| Compound | Early Phase | Mid Phase | Higher Range | Notes |
|---|---|---|---|---|
| Tirzepatide | ~2.5 mg | ~5–10 mg | ~12.5–15 mg | Gradual escalation used in controlled trials. |
| Semaglutide | ~0.25 mg | ~0.5–1.0 mg | ~1.7–2.4 mg | Stepwise increases observed across studies. |
| Retatrutide | ~1–2 mg | ~4–6 mg | ~8–12 mg | Higher ranges linked to increased activity in trials. |
Dose ranges reflect published research observations only. Study protocols typically involve gradual escalation under controlled conditions.
Orders are processed within the UK with secure handling and tracked delivery options.
Quick answers to common questions about our research materials and ordering process.
In the last few years, medications like tirzepatide have drawn...
Read MoreWeight loss remains one of the most searched health topics...
Read MoreRetatrutide is an investigational peptide being developed by Eli Lilly...
Read MoreSemaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has...
Read More